drugset / Trial / NCT00670657

CRITIC - Treatment of Candidemia and Invasive Candidiasis

NCT00670657

Phase 4 Completed 39 enrolled Gilead Sciences
NaSingle-groupOpen-labelTreatment

Summary

Patients will receive 2mg/kg/day IV daily administration of AmBisome® over 30-60 minutes as a reaction to signs/symptoms and positive Candida culture

Timeline

Start
2007-05
Primary completion
2008-12
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Amphotericin B Unknown 2 mg/kg Intravenous

Indications